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Abstract – In this paper, the philosophy of a research in 
pharmacology field, driven by an engineering approach, was 
described along with some case histories and examples. The 
improvement in the testing methods for pharmaceutical 
systems (in-vitro techniques), as well as the proposal and the 
testing of mathematical models to describe the 
pharmacokinetics (in-silico techniques) are reported with the 
aim of pointing out methodologies and tools able to reduce 
the need of  expensive and ethical problematic in-vivo 
measurements. 




I.  INTRODUCTION 
 
The translational medicine is the process of turning 
appropriate biological discoveries into drugs and medical 
devices that can be used in the treatment of patients [1]. 
The basics of this new approach is that “the best results 
are achieved through the cooperative efforts of different 
disciplines, all aimed at the same objective” [1].  
Within this frame, several researches were carried out 
in our group (Transport Phenomena and Processes, 
www.minerva.unisa.it) with the aim of bringing the 
engineering approach  in the early stages of investigations 
in pharmacology and biomedical science [2]. 
Motivated by the guiding principles stated by FDA: 
“The basic principle in an in vivo bioavailability study is 
that no unnecessary human research should be done” [3], 
our research is focused on the development of in-vitro and 
in-silico tools for the investigation of the 
pharmacokinetics of drugs. Both the approaches were 
developed with the aim of limiting the use of unnecessary 
animal and human tests, replacing them with laboratory 
tests [4], [5]. 
With reference to the in-vitro tools, the starting point 
was the use of conventional tests, approved by USP 
(United States Pharmacopoeia). The most widespread 
technique, based on the Apparatus II (thermostated 
vessels stirred by paddles: size and shape of vessel and 
paddle being standardized), has some major drawbacks 
since it cannot simulate the real physiology of 
gastrointestinal tract (GI): since  the motion of fluids (the 
fluid-dynamic) and the biochemical history (mainly the 
pH) are different in the test apparatus and in the real GI 
tract, the absorption across the intestinal wall is not 
simulated at all in the test apparatus. Therefore, there is 
room for significant improvements of the commonly used 
apparatuses and techniques [6]. 
The in-silico approaches require the definition of a 
proper pharmacokinetics model which, after a simple and 
limited validation session (during which some in-vivo 
tests have to be considered), should act as a predictive 
tool. This means that the model, properly calibrated, could 
predict the hematic level of the drug after its 
administration to the human body, even if the 
administration route was changed or the drug delivery 
system was modified with respect to the administration 
route/the drug delivery system adopted during the in-vivo 
tests. 
Aim of this work is to describe the approaches and 
the main results of our group within this two fields. 
 
 
II.  METHODOLOGY 
 
A.  In-vitro methodology 
To test enteric dosage forms, the USP recommend a 
two stage procedure [8]. During the first stage (acid 
stage), the solid dosage form should be  inserted into a 
vessel containing 750 mL of HCl 0.1 M (pH 1.0); then, 
after two hours, the pH has to be  raised to 6.8 by adding 
250 mL of 0.2 M Sodium Phosphate Tribasic (buffer 
stage). 
To allow a full control of the pH into the dissolution 
vessel, 500 mL of a solution buffer with initial pH of 4.8 
was inserted into the vessel (to mimic the real pH in the 
stomach just after the end of a meal), and a given pH 
history was then reproduced by means of an apparatus 
designed and built to the purpose. The apparatus was able 
to dose acid (HCl 2 M) or base (NaOH 2 M) solutions 
into the vessel. After two hours, the sudden pH raise 
which has to mimic the passage toward the intestine was 
realized by adding a given amount of NaOH solution, and 
then allowing the control system to guarantee the 
realization of the set-up value of 6.8. 
To control the pH in the dissolution medium into one 
of the Apparatus 2 vessel, two peristaltic pumps were 
used to dose the acid and the base solutions. The pH is 
measured by using a glass pH – probe. A data acquisition 
board was used to measure and collect the sensor signals. 
A dedicated software was developed to provide the 
control of the pH and the temperature evolution in the ad-
hoc realized device [9]. 
The tests were carried out on commercial tablets 
(extended release - enteric coated, Diclofenac EG, 
Eurogenerici, Milan, Italy). Each tablet contains 100 mg 
of the active molecule (Diclofenac Sodium, DS). The 
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tablets were enteric coated with a polymer insoluble at 
low pH, to avoid the release into the stomach, the other 
excipients being selected to produce a slow release 
(extended release) at higher pH, once the tablet reaches 
the intestine. 
 
B.  In-silico methodology 
The PBPK model developed by our group was based 
on a simple representation of the body, reported in Fig. 1 
[10]. Each of the blocks represents an organ/a tissue/a 
fluid of the body or a group of them: the gastrointestinal 
tract is split into the stomach, the small intestine and the 
large intestine; the gi.c.s block represents the 
gastrointestinal circulatory system; the liver block 
represents the hepatic compartment; the plasma block 
represents the blood and the largely perfused tissues and 
organs; the tissues compartment represents the scarcely 
perfused tissues and organs. The continuous arrows 
represent the mass flow rates between the compartments. 
The dashed arrows represent the drug inlets after 
administration by intravenous or oral route: in the case of 
intravenous injection (i. i.), the only dashed arrow which 
needs to be considered is that entering the plasma 
compartment. Otherwise, in the case of oral assumption 
(o. a.), the dashed arrows which need to be considered are 
those entering the gastric lumen (from ingestion to gastric 
emptying), the small intestine lumen (from gastric 
emptying to small intestine emptying) and the large 
intestine lumen (from small intestine emptying to large 
intestine emptying), depending on where the drug is 
released. The assumption made in doing mass balances 
are that the blocks can be assimilated to continuous stirred 
reactors and that the mechanism of drug transport across 
biological membranes (e.g. the gastrointestinal walls and 




Fig. 1. Schematic of the Physiologically-Based PharmacoKinetic 
(PBPK) model proposed by our group [10] 
The PBPK model consists of the mass balance 
equations on the compartments coupled with their initial 
conditions. Obviously, several parameters need to be 
known in order to solve the system of equations. Namely, 
the model consists in 7 ODEs (Ordinary Differential 
Equations) and it needs the knowledge of 22 parameters, 
some of them could, in principle, be obtained by fitting 
some in-vivo data (taken by literature). The solution of 
model equations has  to be achieved  numerically, and the 





III.  RESULTS AND DISCUSSION 
 
A.  In-vitro results 
One of the most important environmental factor 
affecting the drug release from solid dosage forms, 
administered orally, is the pH. In fact, the drug delivery 
system experiments several pH conditions during its 
traveling along the GI tract: a low pH in the stomach 
(about 4-5), followed by an almost neutral pH in the small 
intestine, followed by a further rise in pH ( about 7) in the 
large intestine. Since the adsorption in the stomach is not 
very effective, to avoid drug degradation the ideal drug 
delivery system should not release any drug in the 
stomach (at low pH), then it should release its drug 
content in the small intestine where the absorption is the 
largest (the best would be if the release takes place at a 
constant rate, to replace exactly the drug metabolized: the 
so-called zero-order drug delivery system). Only in 
special cases, the drug release has to be targeted to the 
colon (e.g. to treat localized diseases). Therefore, the 
design of drug delivery systems has been addressed to the 
production of the so-called “enteric” systems, i.e. tablets 
which does not release any drug at the low pH values 
expected in the stomach, delivering their drug content 
once the pH raises to neutral values. 
 
 
Fig. 2. pH histories during the tests: dotted line, USP protocol; 
dashed line, experimental history in human GI tract[7]; continuous line, 
the pH history simulated in the novel in-vitro device [9] 
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To test the effectiveness of such drug delivery 
systems, a two stages protocol (briefly summarized in the 
Methodology section) is reported in the USP. In Fig. 2 the 
related pH history is reported as a dotted line: the pH was 
kept on pH 1.0 for the first two hours, to mimic the 
passage in the stomach; then it was raised to 6.8 to mimic 
the passage in the small intestine. In the real human 
physiology, the pH in the stomach is not equal to 1.0. In 
fed state, it is roughly 4.8-5.0 and it starts to decrease 
after a meal. Then, once the bolus passes the pylorus, the 
pH increases toward neutral values. Therefore, a more 
realistic pH history is drawn in Fig. 2 as a dashed line, 
taken from literature, measured in-vivo after a light 
meal[7]. It is evident that the decrease in pH is not very 
fast, and during the two hours of staying in the stomach, 
the pH barely reach the value of pH 2.0. The set-up 
described in the Methodology section allowed us to 
simulate the realistic pH history in the vessel of Apparatus 
II: the “real” pH history is reported as a black continuous 
line.  
Therefore, we could analyze the release kinetics  in 
the two environments, with different pH evolutions: 1) 
using the conventional enteric test (the pH history being 
given by the dotted line in Fig. 2); and 2) using the novel 
test protocol depicted above (the pH history being given 
by the continuous line in Fig. 2). The results of these two 
tests are reported in Fig. 3. The full circles are the 
experimental result of the release kinetics observed by the 
traditional (USP Method A) protocol, the diamonds are 
the experimental result of the release kinetic data 
observed by the novel test protocol. It is evident that: 
1. in the conventional USP test, during the acid stage, a 
very little amount of drug is released (less than 10 
mg, the total content being 100 mg). The release in 
the buffer stage is well controlled (after 8 hours, less 
than 90 mg were released). 
 
 
Fig. 3. The release kinetics obtained by the conventional method 
(USP Method A, full circles and dashed line) and by the novel technique 
(diamonds and continuous line). [9] 
2. in the novel test (which mimics the real physiology 
better than the conventional test), during the acid 
stage, the drug release is high (20 mg) and the 
remaining drug is released during the buffer stage 
very quickly (less than one hour to release about 80 
mg). 
Summarizing, the release in the real stomach would 
be more than the twice the release in the conventional in-
vitro test (USP); and the release in the real intestine would 
occur in a very short time (in the conventional in-vitro test 
it takes more than 8 hours). This could be due to the fact 
that the coating technique is insufficient to guarantee the 
enteric behavior, as the excipients have to be resistant to 
unexpected high pH levels. Possible solutions could 
consist in the use of different preparation 
method/materials (e.g. microencapsulation / polyacrilic 
polymers), or in the indication of a proper administration 
therapy (e.g. the tablet should be dosed one hour after the 
end of the meal). It should be noted that the 
administration of these tablets, fully compliant with the 
USP tests, could be ineffective; and that a deeper 
understanding of what happens once the pill has been 
swallowed derived from the novel “engineering” 
approach to the problem” [9]. 
 
B.  In-silico results 
Usually, pharmacokinetic modeling is aimed to 
establish correlations between the in-vitro release data 
such as the release reported in Fig. 3 with in-vivo hematic 
drug concentration (or different measurements of the drug 
in the bodies of living beings). If the model consists in 
purely mathematical equations, without any physical 
meanings, they are called IVIVC (In-Vitro In-Vivo 
Correlations) and they are classified on the basis of their 
ability to correlate the two profiles. Regulatory boards 
(FDA [12], USP [13]) accept only the higher-level 
correlations (the so-called level A IVIVC) for Scale-Up 
and Post-Approval Changes (SUPAC) which “can be 
justified without the need for additional human studies”. 
 
Fig. 4. In-vitro release kinetics of Diltiazem from three different 
tablets. Symbols: experimental data [14], curves: fitting. 
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Fig. 5. Hematic concentrations of Diltiazem in-vivo, after tablet 
administrations. Symbols: experimental data, curves: model calculations. 
 
Of course, a PK model able to correlate the in vitro 
dissolution profile and the in vivo plasma evolution, will 
play the same role of a Level A IVIVC, but being more 
physically based, it would be of major interest for 
researchers. This was the motivation of the design and the 
coding of the model whose main parts are reported in the 
scheme of Fig. 1. 
For example, Fig. 4 reports the in-vitro release kinetic 
data and Fig. 5 reports the related in-vivo hematic 
concentration of Diltiazem administered orally to healthy 
volunteers. The symbols in both the graphs are 
experimental data, taken from ref. [14]; Diltiazem is a 
calcium channel blockers, used among other therapies in 
the treatment of hypertension. In Fig. 4 three series of 
date were displayed, representing the in-vitro release 
kinetics of three different tablets, labeled ‘fast’, ‘medium’ 
and ‘slow’ because of the decreasing release rate. 
Similarly, in Fig. 5 three series of data are displayed, 
representing the in-vivo hematic concentration evolution 
due to the administration of the three different tablets 
before tested in-vitro (the main difference between the 
three evolutions being the maximum drug hematic 
concentration and the Area Under the Curve, which is a 
measure of bioavailability). 
The process of pharmacokinetic modeling required 
some steps: 
 
1. First of all, the in-vitro release kinetics was fitted by 
suitable mathematical expression. This step was 
required because the in-vitro data are inputs of the 
physiologically base pharmacokinetics (PBPK) 
model, and scattered experimental data do not play 
well in numerical code, mainly because of sudden 
changes in derivative. Results of this fitting session 
are the curves in Fig. 4. 
 
2. Then, the PBPK model was used to simulate the 
hematic concentration due to the administration of 
the ‘medium’ rate tablet. During this step, the model 
parameters were adjusted to enable  the model 
predictions to describe the real in-vivo drug 
concentration evolution. Result of this fitting 
session is the dashed curve in Fig. 5 which describe 
the in-vivo behavior. It is worth to note that this step 
does require the analysis of some results of in-vivo 
experiments. 
 
3. At this point, the model is predictive, i.e. it should be 
able to predict the drug hematic concentration after 
the administration of a tablet with release kinetics 
different than the ‘medium’ rate one. Actually, the 
curves in Fig. 5 for ‘fast’ and ‘slow’ rate 
administration (respectively, continuous and dotted 
curves) have been calculated with the model without 
any further optimization work. 
 
It is worth to note that the model predicts the real 
maximum drug concentrations and AUCs for ‘fast’ and 
‘slow’ rate tablets accurately enough. As matter of facts, 
the predictions offer the same level of accuracies of a 
Level A IVIVC, therefore the PBPK model, in principle, 
could be used in SUPAC process accordingly with 
regulatory boards.  
The two series of data (‘fast’ and ‘slow’ rate) are thus 
unnecessary: the availability of the tool constituted by the 
PBPK model could avoid a large number of in-vivo 
experiments, which are ethically problematic and resource 
asking. 
 
IV.  CONCLUSIONS 
 
The translational research could be a powerful tool 
for researchers over all the world to guide the process 
“from bench to bedside”, i.e. the translation of non-human 
research finding, from the in-vitro and from in-silico 
studies, into human therapies. The translational medicine 
found its roots into interdisciplinarity, since it is based on 
the creation of something new by thinking across the 
boundaries between different scientific disciplines. Within 
this contest, the engineering  approach is  of tremendous 
utility in pharmacology and in biomedical science. 
In this work, two case histories are reported.  
In the first one, an improvement in the in-silico 
testing for solid dosage forms showed how a tablet, 
designed to give a well-defined release kinetics – and 
proved able to work efficiently by traditional test methods 
– was found very ineffective once tested in the novel test 
method, which better reproduces real physiological 
conditions. By this study, the need for   proper drugs 
administration therapies was pointed out. 
In the second case history, a simple and effective 
physiologically based pharmacokinetic model was 
proposed and tested; it was proved to describe nicely the 
hematic levels of several drugs, even for different 
administration routes. The model could be the basis for 
more detailed pharmacokinetic studies (varying also inter-
individual parameters such as age, gender and weight) 
toward the development of the personalized therapies. 
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